Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Crossmark Global Holdings Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 23.7% during the ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

As a next step, they plan to conduct tests in larger animals. The authors acknowledge funding from the U.S. National ...